|
BOD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.73128178460047E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.81756864903582E-13 |
| Normal-vs-Stage2 |
6.719700E-03 |
| Normal-vs-Stage3 |
1.5967227540159E-12 |
| Normal-vs-Stage4 |
1.63724589441472E-12 |
| Stage1-vs-Stage2 |
4.422000E-02 |
| Stage1-vs-Stage3 |
3.386000E-01 |
| Stage1-vs-Stage4 |
6.324600E-03 |
| Stage2-vs-Stage3 |
1.715790E-02 |
| Stage2-vs-Stage4 |
1.100610E-03 |
| Stage3-vs-Stage4 |
1.117600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11355369369903E-12 |
| Normal-vs-AfricanAmerican |
2.83040000004231E-06 |
| Normal-vs-Asian |
6.44849995623531E-09 |
| Caucasian-vs-AfricanAmerican |
7.325800E-01 |
| Caucasian-vs-Asian |
4.135400E-01 |
| AfricanAmerican-vs-Asian |
8.934400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.04880598334512E-13 |
| Normal-vs-Female |
4.29201119089839E-12 |
| Male-vs-Female |
1.841810E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.3365753776261E-12 |
| Normal-vs-Age(41-60Yrs) |
1.7725043655048E-11 |
| Normal-vs-Age(61-80Yrs) |
7.71719999015374E-09 |
| Normal-vs-Age(81-100Yrs) |
1.456210E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.787200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.123000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.030600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.425800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.058200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.814000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.228600E-04 |
| Classical-VS-Follicular |
5.535600E-03 |
| Classical-VS-Other |
9.985800E-01 |
| Classical-VS-Normal |
1.62481139653892E-12 |
| Tall-VS-Follicular |
2.80009999997777E-06 |
| Tall-VS-Other |
1.319600E-01 |
| Tall-VS-Normal |
1.06581410364015E-14 |
| Follicular-VS-Other |
3.909800E-01 |
| Follicular-VS-Normal |
4.804600E-04 |
| Other-VS-Normal |
2.477400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.5040999990521E-08 |
| Normal-vs-N1 |
3.66373598126302E-15 |
| N0-vs-N1 |
3.68980000000629E-05 |
|
|
